- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02956954
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (MyFABT1)
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®)
Anderson Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase. AFD can involve various organs and lead to a series of clinical abnormalities. Left ventricular hypertrophy in middle-aged men is one of its life threatening complications. It was shown that pending the absence of myocardial replacement fibrosis, substitution therapy could improve myocardial morphology and function as well as exercise capacity. Today, there is no available marker of the efficacy of the treatment on the heart morphology and function.
The T1 time (or longitudinal relaxation time) is one of the major components of the image formation in Magnetic Resonance Imaging (along with T2 time and proton density). Several techniques have been described to assess the myocardial T1-time.
One of them called MOLLI (Modified Look Locker Inversion Recovery), was made available in research centres by the Siemens company. In a study published in 2013, Sado et al. showed in a series of various conditions (hypertension, AFD, hypertrophic cardiomyopathy, AL amyloidosis, aortic stenosis and healthy volunteers) that a septal T1 below a threshold of 940ms could discriminate AFD patients. No overlap was shown with other conditions in this study. Our experience with T1 mapping supports that finding (even though our threshold could be slightly different), and we could recently detect by MRI a number of AFD patients, some of them with hypertrophy, some others without hypertrophy. The effect of Replagal® on the T1 relaxation time remains unknown.
The purpose of that study was to follow-up the heart morphology, function and myocardial T1 relaxation time in a population of treated/untreated patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Nicolas DACHER, Pr
- Email: jean-nicolas.dacher@chu-rouen.fr
Study Locations
-
-
-
Rouen, France
- Recruiting
- ROUEN university hospital
-
Contact:
- Jean-Nicolas DACHER, Pr
-
Principal Investigator:
- Jean-Nicolas DACHER, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with proven Anderson Fabry Disease
- Patient with no Agalsidase alpha (Replagal®) treatment or
- Patient with Agalsidase alpha (Replagal®) treatment ongoing
Exclusion Criteria:
- Pace Maker / Implantable Cardiac Defibrillator
- Claustrophobia
- Ocular foreign body
- Allergy to gadolinium chelates
- Pregnancy ongoing
- Age < 18 years l
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient treated with Enzyme replacement therapy
Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
|
Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)).
The treatment is prescribed in routine and not specially for the protocol
Magnetic Resonance Imaging will be assessed every 6 months during 2 years
|
Sham Comparator: Patient no treated with Enzyme replacement therapy
Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
|
Magnetic Resonance Imaging will be assessed every 6 months during 2 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference from baseline in Septal myocardial T1 relaxation time
Time Frame: 24 months
|
Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference from baseline in Septal myocardial T1 relaxation time
Time Frame: 6 months
|
Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient
|
6 months
|
Difference from baseline in Septal myocardial T1 relaxation time
Time Frame: 12 months
|
Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient
|
12 months
|
Difference from baseline in Septal myocardial T1 relaxation time
Time Frame: 18 months
|
Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Nicolas DACHER, Pr, ROUEN university hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Fabry Disease
Other Study ID Numbers
- 2016/092/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anderson-Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
Brett CristRecruiting
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael
Clinical Trials on Enzyme replacement therapy (Agalsidase alpha (Replagal®))
-
Ulla Feldt-RasmussenCompleted
-
Rigshospitalet, DenmarkCompletedFabry DiseaseDenmark
-
Idorsia Pharmaceuticals Ltd.Completed
-
SanofiRecruitingFabry DiseaseItaly, United States, Austria, China, Czechia, Denmark, France, Germany, Greece, Japan, Korea, Republic of, Netherlands, Norway, Spain, Taiwan, Turkey, United Kingdom, Canada, Poland
-
Federal Research and Clinical Center of Physical-Chemical...Moscow State University of Medicine and DentistryCompletedChronic Pancreatitis | Pancreatic Exocrine InsufficiencyRussian Federation
-
ShireCompletedMucopolysaccharidosis IIUnited States, United Kingdom, Brazil, Germany
-
Tripler Army Medical CenterUniversity of VirginiaUnknownRestless Legs SyndromeUnited States
-
AbbVieVIVUS LLC; Cystic Fibrosis Foundation; Digestive Care, Inc.; Nestle Health ScienceTerminated
-
ShireCompletedGaucher Disease, Type 3Egypt, India, Tunisia
-
Centro Hospitalar e Universitário de Coimbra, E...University of CoimbraRecruitingExocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement TherapyImmunology | Acute Pancreatitis | Exocrine Pancreatic Insufficiency | Gut MicrobiotaPortugal